KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Treasury Shares: 2011-2024

Historic Treasury Shares for Alnylam Pharmaceuticals (ALNY) over the last 12 years, with Dec 2024 value amounting to $1.7 million.

  • Alnylam Pharmaceuticals' Treasury Shares rose 66.99% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year increase of 66.99%. This contributed to the annual value of $1.7 million for FY2024, which is 66.99% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Treasury Shares stood at $1.7 million for FY2024, which was up 66.99% from $1.0 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Treasury Shares ranged from a high of $1.7 million in FY2024 and a low of $1.0 million during FY2023.
  • Its 3-year average for Treasury Shares is $1.3 million, with a median of $1.2 million in 2022.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Treasury Shares soared by 67.42% in 2020 and then dropped by 13.56% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Treasury Shares (Yearly) stood at $1.0 million in 2020, then climbed by 8.92% to $1.1 million in 2021, then climbed by 5.19% to $1.2 million in 2022, then decreased by 13.56% to $1.0 million in 2023, then spiked by 66.99% to $1.7 million in 2024.